The Phenothiazine Antipsychotic Family
Tricyclic Antipsychotics — Dopamine D2 Receptor Blockade and SAR
## Overview
Phenothiazine antipsychotics represent the first effective pharmacological treatment for schizophrenia, following the serendipitous discovery of chlorpromazine's antipsychotic properties by Henri Laborit and Jean Delay in 1952. These tricyclic sulfur-nitrogen heterocycles block multiple central receptors—dopamine D2, histamine H1, muscarinic M1, and adrenergic α1—but their antipsychotic efficacy is primarily attributed to D2 receptor blockade in the mesolimbic pathway. While largely superseded by second-generation (atypical) antipsychotics, phenothiazines remain in use for acute agitation, treatment-resistant schizophrenia, and as antiemetics.
## Core Scaffold: Phenothiazine Tricycle
The phenothiazine ring is a dibenzo-fused thiazine: two benzene rings bridged by sulfur and nitrogen, forming a non-planar butterfly or folded conformation. This conformation is critical for receptor interaction—it mimics the preferred dihedral arrangement of dopamine in the D2 binding pocket. The nitrogen at position 10 is the attachment point for the basic side chain, and the 2-position of one benzene ring is the primary site for potency-modifying substitution.
## D2 Receptor Pharmacology
Dopamine D2 receptor blockade in the mesolimbic pathway (nucleus accumbens) underlies antipsychotic efficacy against positive symptoms (hallucinations, delusions). Blockade in the nigrostriatal pathway causes extrapyramidal side effects (EPS: parkinsonism, akathisia, dystonia, tardive dyskinesia). Blockade in the tuberoinfundibular pathway causes hyperprolactinemia. All first-generation antipsychotics (FGAs), including phenothiazines, carry substantial EPS and tardive dyskinesia risk because they are relatively non-selective D2 blockers—D2 occupancy >80% (required for antipsychotic efficacy) is close to the threshold for EPS (>75%).
## Side-Chain SAR and Selectivity Profiles
The three major phenothiazine subclasses differ in their N10 side chain terminus: (1) **Aliphatic amines** (chlorpromazine, promazine)—dimethylaminopropyl terminus; highest sedation, anticholinergic effects, and orthostatic hypotension; lowest EPS; (2) **Piperidines** (thioridazine, mesoridazine)—piperidine terminus; moderate sedation; avoided due to QT prolongation (hERG block by the piperidyl ring C2-SCH3 metabolites); (3) **Piperazines** (fluphenazine, trifluoperazine, perphenazine)—piperazinyl terminus; least sedating; highest EPS risk; highest D2 potency.
## Long-Acting Injectables (LAIs)
A major innovation in phenothiazine pharmacology was fluphenazine decanoate, a prodrug ester formed from the 2'-hydroxyl group of fluphenazine and decanoic (caprylic) acid. Administered by deep intramuscular injection, the ester is slowly hydrolyzed by plasma and tissue esterases over 2–4 weeks, providing sustained plasma levels. LAIs fundamentally changed the management of schizophrenia by eliminating the issue of daily oral adherence—a major driver of relapse. This prodrug strategy was later applied broadly to atypical antipsychotics (aripiprazole lauroxil, paliperidone palmitate).
## Antiemetic and Non-Antipsychotic Uses
Phenothiazines with lower CNS penetration (prochlorperazine) or designed for peripheral D2 blockade are used as antiemetics. The chemoreceptor trigger zone (CTZ) of the area postrema lacks a blood-brain barrier, allowing prochlorperazine to block CTZ D2 receptors without full CNS penetration. Promethazine, with an H1-dominant profile, is used for motion sickness and as a sedating premedication.
## Key Takeaways
- The phenothiazine butterfly scaffold mimics dopamine's binding geometry at the D2 receptor; N10-propyl side chain length is optimal
- 2-CF3 (vs 2-Cl) confers higher D2 potency and eliminates photoallergic sensitization
- Piperazine terminus increases D2 potency and EPS risk; aliphatic amine terminus increases sedation/anticholinergic effects
- Fluphenazine decanoate established the long-acting injectable (LAI) prodrug strategy via ester hydrolysis from IM depot
- Phenothiazines were superseded by atypical antipsychotics for long-term use but remain important for acute agitation and antiemesis
Tóm tắt SAR
Key SAR findings for the phenothiazine family:
- The phenothiazine tricyclic scaffold adopts a butterfly conformation that mimics the bioactive conformation of dopamine in the D2 receptor binding pocket.
- A basic side chain at N10 of 2–3 carbons (propyl optimum) ending in a piperazine, piperidine, or dimethylamino terminus is required for D2 affinity; two-carbon chain is inactive, four-carbon reduces potency.
- The 2-position on the phenothiazine ring is the primary site for selectivity modulation: electron-withdrawing groups (CF3, Cl) in the 2-position increase D2 potency ~3-5x vs unsubstituted; trifluoromethyl (trifluoperazine, fluphenazine) provides the highest antipsychotic potency.
- 2-CF3 substituents also reduce the incidence of allergic skin reactions seen with 2-Cl (chlorpromazine) by abolishing photoallergic sensitization.
- Piperazine terminal amine (vs dimethylamino in chlorpromazine) reduces sedation and anticholinergic effects while increasing extrapyramidal side effect (EPS) liability due to higher D2 selectivity.
- Long-acting injectable (LAI) fluphenazine decanoate converts the 2'-OH of fluphenazine to a C10-fatty acid ester, providing slow hydrolysis and ~2-4 week duration.